CBRE vs CHRS · P/E 43, rev $21.75B vs rev $26.6M
CBRE Group Inc Class A (CBRE) versus Coherus BioSciences Inc (CHRS) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. CHRS currently screens at market cap $223.7M.
Not investment advice. Open the CBRE and CHRS stock pages for the full models.
Not investment advice.